Anti‑tumor Activity of CBI‑1214 T Cell Engager in Participants With Advanced or Metastatic MSS/MSI‑L Colorectal Cancer
The FDA has approved the combination of nivolumab and ipilimumab as first‑line therapy for patients with MSI‑H or dMMR advanced colorectal cancer.
A new FDA approval endorses the nivolumab plus ipilimumab combination as the preferred first‑line treatment for patients with advanced microsatellite instability–high or mismatch‑repair deficient colorectal cancer. Based on the CheckMate‑8HW phase III randomized trial, the dual therapy significantly improves progression‑free survival compared with nivolumab alone (68% versus 51% at 3 years), albeit with higher rates of serious adverse events. This landmark decision could shift clinical practice, underscoring the importance of accurate MSI‑H/dMMR testing.
The approval introduces a highly effective immunotherapy option that may extend progression‑free survival and potentially improve overall survival in a subgroup of colorectal cancer patients who previously had limited choices. It also reinforces MSI/dMMR testing as a critical step in personalized treatment planning.
Bizonyítékszint: Klinikai vizsgálat. Formális klinikai vizsgálati eredmény.
Kapcsolódó jelek
- Encorafenib, Binimetinib, and Cetuximab in BRAF V600E‑Mutated Colorectal Cancer
- Current and emerging therapeutic approaches for colorectal cancer: A comprehensive review
- Three Versus 6 Months of Adjuvant Oxaliplatin‑Fluoropyrimidine Chemotherapy for Colorectal Cancer: Final Results of SCOT—An International, Randomized, Phase III, Noninferiority Trial
- Duration of Adjuvant Chemotherapy for Stage III Colon Cancer
- Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics